Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses

Summary

This prospective study aims to characterize blood brain barrier (BBB) disruption in patients with newly diagnosed glioblastoma multiforme undergoing surgical resection. The study integrates advanced MRI, circulating BBB biomarkers, neurocognitive assessment, and molecular analysis of tumor tissue to investigate relationships between BBB integrity, tumor biology, and neurological function. Participants will undergo serial assessments before surgery, after surgery, and following radiotherapy. Tumor tissue collected during standard-of-care resection will undergo immunohistochemical and transcriptional

Interventions

• Multimodal Blood Brain Barrier Assessment · DIAGNOSTIC_TEST

  A standardised multimodal diagnostic assessment designed to characterize blood brain barrier integrity in patients with newly diagnosed glioblastoma. The intervention includes advanced contrast enhanced MRI, serial blood sampling for measurement of blood-brain barrier and neuronal injury biomarkers (including S100β, GFAP, UCHL1, amyloid beta, phosphorylated tau, and neuron-specific enolase), neurocognitive assessments, and immunohistochemical and transcriptional analyses of tumor tissue obtained during standard-of-care surgical resection. Assessments are performed longitudinally before surgery, after surgery, at 72 hours, at 4 weeks, and following completion of radiotherapy.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Adult patients aged 18 years or older.
* Newly diagnosed glioblastoma.
* Selected for surgical tumor resection.
* Able and willing to provide written informed consent.
* Able to undergo study assessments and follow-up procedures.

Exclusion Criteria:

* Contraindication to magnetic resonance imaging.
* Confusion, delirium, or altered state of consciousness that interferes with the ability to provide informed consent.
* Any condition that, in the opinion of the investigator, would prevent completion of study procedures or compromise participant safety.

Sites (1)

• Beaumont RCSI Cancer Centre, Beaumont, Ireland · RECRUITING